Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial)

NCT04082780 is registered in ClinicalTrials.gov with Hunter Holmes Mcguire Veteran Affairs Medical Center as lead sponsor.

NCT NCT04082780
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04082780 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Randomized Placebo-Controlled Trial of Rifamycin SV MXX in Minimal Hepatic Encephalopathy (RIVET Trial)
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Phase
Phase 2
Overall status
Completed
Start date
September 1, 2019
Completion date
April 28, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cirrhosis, liver, hepatic encephalopathy